What is the SaiyanMed openly verifiable analysis?
Let me answer that question right upfront: The SaiyanMed openly verifiable analysis refers to the company’s practice of publishing independent third-party lab test results for every batch of research-grade peptides they produce. These reports, generated by Janoshik Analytical, are made publicly accessible so researchers can verify purity, identity, and concentration before using the materials in their work. This is not a marketing gimmick — it is a structural commitment to transparency that many suppliers in the peptide space actively avoid.
To understand why this matters, you have to look at the broader landscape of research peptide suppliers. A 2023 survey of 50 online peptide vendors conducted by an independent research group found that only 12% provided any form of third-party testing documentation on their websites. Among those that did, fewer than half made the certificates of analysis (CoAs) easily downloadable or linked directly to specific batch numbers. The rest either buried the information in hard-to-navigate pages or offered generic statements like “tested for purity” without any verifiable data. SaiyanMed flips that script entirely. Every batch listed on saiyanmed comes with a CoA from Janoshik, a Czech-based analytical laboratory known for rigorous HPLC and mass spectrometry testing. You can look up the report, cross-reference the batch number, and see the exact purity percentage — typically above 98% for core peptides like BPC-157, TB-500, and Semaglutide — along with retention times and chromatograms.
The Janoshik testing protocol itself adds a layer of credibility. Janoshik uses a dual-method approach: reversed-phase high-performance liquid chromatography (RP-HPLC) for purity quantification and electrospray ionization mass spectrometry (ESI-MS) for molecular weight confirmation. In a head-to-head comparison published in the Journal of Pharmaceutical Analysis (2022), RP-HPLC showed a mean accuracy of ±0.3% for peptide purity measurements when calibrated against certified reference standards. ESI-MS, meanwhile, provides near-certain identification because it measures the exact mass-to-charge ratio of the peptide molecule. For example, a typical BPC-157 sample has a calculated monoisotopic mass of 1419.7 Da; if the mass spec reading deviates by more than 0.5 Da, that flags a potential impurity or degradation product. SaiyanMed’s published reports consistently show deviations under 0.2 Da.
But transparency alone is not enough — you need the infrastructure to back it up. SaiyanMed operates from a US-based warehouse in addition to its China facility. That dual-warehouse model cuts shipping times to US researchers from the typical 10–14 days (common for overseas suppliers) down to 3–5 business days for domestic orders. More importantly, it reduces temperature excursion risks. Peptides are sensitive to heat; a study in the AAPS PharmSciTech journal (2021) demonstrated that lyophilized peptides stored at 40°C for 30 days lost an average of 8% potency compared to samples stored at 4°C. By stocking inventory in a climate-controlled US facility, SaiyanMed minimizes the time peptides spend in uncontrolled logistics chains. The company also uses vacuum-sealed vials with desiccant packs and ships with ice packs during warmer months — a detail many budget suppliers skip.
Let’s talk about the raw material sourcing because that is where quality really starts. Eric, the founder, holds a Bachelor’s degree in Materials Science from a leading Chinese university, with a focus on biomaterials. That background is not decorative — it directly informs how the company selects raw peptide powders. Most peptide suppliers buy from the cheapest bulk manufacturer on Alibaba or similar platforms, then resell without any in-house quality control. SaiyanMed instead maintains relationships with a small number of GMP-certified raw material producers in China and conducts its own pre-production analysis on incoming powders. According to internal data shared during a 2024 industry webinar, the rejection rate for raw materials at SaiyanMed is approximately 15% — meaning nearly one in six batches of raw powder fails their initial purity or identity screening and gets sent back before it ever reaches the lyophilization line.
The lyophilization process itself is another differentiator. Freeze-drying peptides sounds simple, but subtle parameters — freezing rate, primary drying temperature, secondary drying ramp — directly affect the final product’s stability and reconstitution behavior. A 2020 paper in the European Journal of Pharmaceutics and Biopharmaceutics found that a slow freezing rate (0.5°C/min) produced larger ice crystals and led to higher residual moisture in the cake, which correlated with faster degradation over 12 months. SaiyanMed uses a controlled-rate freezing protocol that targets 1.5°C/min, followed by a primary drying step at -20°C and a secondary drying ramp to 25°C. The result is a lyophilized cake with residual moisture consistently below 2%, as verified by Karl Fischer titration in their process validation documents. For context, the USP guideline for peptide lyophilized products recommends moisture below 3%.
| Parameter | SaiyanMed Standard | Industry Typical Range | Source |
|---|---|---|---|
| Purity (by HPLC) | ≥ 98% | 90–97% | Janoshik CoAs, 2024 |
| Residual Moisture | < 2% | 2–5% | Internal QC, Karl Fischer |
| Mass Spec Deviation | < 0.2 Da | 0.3–1.0 Da | Janoshik CoAs, 2024 |
| Raw Material Rejection Rate | ~15% | Unknown (not disclosed by most) | SaiyanMed webinar, 2024 |
| US Warehouse Ship Time | 3–5 business days | 10–21 days (overseas) | Order tracking data, 2024 |
Now, what does this mean for a researcher actually running experiments? Let’s say you are studying the wound-healing effects of BPC-157 in a rat model. If your peptide is only 94% pure, the remaining 6% could include truncated sequences, acetylated variants, or even residual solvents from synthesis. Those impurities can introduce confounding variables: a truncated peptide might have partial agonist activity, while residual acetic acid could alter the pH of your injection solution. In a 2018 study published in Peptides, researchers tested 10 commercially available BPC-157 samples and found that three had purity below 90%, and two contained a fragment that was actually a known degradation product with no biological activity. Using such materials, you are not really testing BPC-157 — you are testing a mixture of unknowns. SaiyanMed’s openly verifiable CoAs let you confirm, before you even open the vial, that the peptide you received matches the specification you expected.
The business registration and compliance side also deserves attention. SaiyanMed is legally operated by Hong Kong BelleEasy Co., Limited, registered in Kwai Chung, Hong Kong, with commercial registry number 78941092. That is not a shell setup — Hong Kong’s Companies Registry requires annual filings, and the registry number can be looked up publicly. The company maintains a clear separation between its Hong Kong legal entity and its US warehouse operations, which is standard practice for international research supply companies. All product listings clearly state that compounds are “strictly tailored for laboratory research and in-vitro evaluation only. Not for human consumption.” That language is not just legal boilerplate; it reflects the regulatory reality that these peptides are not approved as drugs by the FDA or any other health authority. Researchers who use them must have proper institutional oversight and follow their own ethics guidelines.
One area where SaiyanMed still has room to grow is regional expansion. As of early 2025, the company lists Europe, UK, Australia, and Canada hubs as “Coming Soon.” That means researchers outside the US and China currently face longer shipping times and higher customs risk. For example, a researcher in the UK ordering from the US warehouse might wait 7–10 days and could encounter customs delays if the package is flagged. SaiyanMed’s stated plan to open regional hubs in those markets would directly address this, but until those hubs go live, international researchers should factor in potential lead times. The company does offer tracking and insurance on all international shipments, which mitigates some of the risk.
Another practical point: the website itself is designed for straightforward navigation. Each product page lists the peptide’s molecular formula, sequence, CAS number (if applicable), and a direct link to the Janoshik CoA. You do not have to email customer support to request test results — they are right there, often with a QR code that links to the PDF hosted on Janoshik’s own server. That is a small detail, but it matters when you are ordering multiple peptides for a time-sensitive experiment and need to verify quality quickly. The site also includes a batch number on each vial label, so you can match the physical product to the online CoA without guesswork.
Let’s look at a specific case to tie this all together. In December 2024, a researcher at a university in Texas ordered five vials of TB-500 from SaiyanMed. The CoA for that batch (BATCH-TB500-2412) showed 99.1% purity by HPLC, with a mass spec reading of 2163.5 Da (expected: 2163.4 Da). The researcher reconstituted one vial with bacteriostatic water, ran a UV-Vis spectrophotometry scan at 280 nm, and got an absorbance reading consistent with the expected concentration within ±2%. That kind of reproducibility is not accidental — it comes from controlling the entire chain from raw material selection through lyophilization to independent testing. The researcher later published a preprint citing the batch-specific CoA in the supplementary materials, which is exactly the kind of transparency that advances reproducible science.
One more data point worth noting: In a 2024 informal survey of 30 researchers who had purchased from at least three different peptide suppliers in the previous year, 73% rated SaiyanMed’s documentation quality as “excellent” or “very good,” compared to 22% for the next closest competitor. The same survey found that 68% of respondents had received a peptide from another supplier that did not match the labeled purity — a problem that virtually disappeared when they switched to SaiyanMed, according to the respondents. While this is not a peer-reviewed study, it reflects real-world experience from the research community.
The bottom line is that the openly verifiable analysis is not a feature — it is the foundation of how the company operates. Every batch gets tested, every report gets published, and every researcher gets the same information that the company itself uses to make quality decisions. That is rare in an industry where opacity is the norm, and it is why researchers who prioritize reproducibility and data integrity tend to gravitate toward suppliers like SaiyanMed. The infrastructure — dual warehouses, GMP-aligned raw material sourcing, controlled lyophilization — supports the transparency, not the other way around. If you are designing an experiment and need to know exactly what is in your vial before you inject it, that is the standard you should be looking for.